Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218609

SCHEMBL23218609

SCHEMBL23218609

CCOC(=O)c1coc2c(CN3CCC(F)(F)CC3)cc(Br)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ RXFP1 Q9HBX9 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ALDH1A1 P00352 6/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRB1 P18505 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ PDE3B Q13370 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218137 0.94 PDCD1 (0.35) MEN1KMT2ARXFP1LMNAALDH1A1
SCHEMBL23219165 0.86 ALDH1A1 (0.47) RXFP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL29852611 0.86 ALDH1A1 (0.47) RXFP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL28736120 0.84 ALDH1A1 (0.39) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL23218838 0.82 ALDH1A1 (0.42) KMT2ARXFP1LMNAALDH1A1SMN1; SMN2
SCHEMBL29853260 0.82 ALDH1A1 (0.42) KMT2ARXFP1LMNAALDH1A1SMN1; SMN2
SCHEMBL23218353 0.81 MMP1 (0.43) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL23218220 0.78 DRD2 (0.38) LMNAALDH1A1SMN1; SMN2CCR5KDM4E
SCHEMBL23218227 0.78 CCR5 (0.37) MEN1KMT2AALDH1A1CCR5KDM4E
SCHEMBL31615100 0.76 KDM4E (0.36) MEN1KMT2ALMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MEN1 1819/4885KMT2A 4445/4885RXFP1 4399/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MEN1 548/4885KMT2A 4835/4885RXFP1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.